Published on 19 Dec 2022 on Benzinga via Yahoo Finance
After Five Years Of Collaboration, Sanofi & Innate Pharma Expand Oncology Pact With Additional...
Innate Pharma SA (NASDAQ: IPHA) and Sanofi SA (NASDAQ: SNY) have expanded their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate's ANKET (Antibody-based NK Cell Engager Therapeutics) platform.Sanofi will also have the option to add up to two additional ANKET targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing, and commercialization.Under the terms of the new license agreement, Innate will receive €25 million upfront payment and up to €1.35 billion total in preclinical, clinical, regulatory, and commercial milestones plus royalties on potential net sales.Innate and Sanofi signed the first NK cell engagers collaboration in 2016 for the generation and evaluation of up to two bispecific NK cell engagers, which are currently being evaluated by Sanofi's R&D team, with one of these molecules already in clinical studies.A Phase 1/2 trial by Sanofi is ongoing, evaluating IPH6101/SAR'579 (SAR443579), the first NKp46/CD16-based CD123-targeted ANKET NK cell engager, for relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high-risk myelodysplastic syndrome.In the summer of 2022, Sanofi decided to progress IPH6401/SAR'514 (SAR445514) into an investigational new drug (IND)-enabling studies.Under the terms of the original license agreement, Sanofi is responsible for the development, manufacturing, and commercialization of products resulting from the research collaboration.Innate Pharma will be eligible for up to €400 million in development, commercial milestone payments, and royalties on net sales. To date, €13 million milestone payments to Innate have been announced.Price Action: IPHA shares are up 35.8% at $2.58 during the premarket session on the last check Monday. SNY shares closed at $46.98 on Friday.
See more from Benzinga